Description
Adagrasib is a inhibitor of KRASG12C, which is a notoriously difficult to treat cancerous mutation.
Adagrasib
Product ID A121008
Cas No. 2326521-71-3
Purity ≥99%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2326521-71-3 |
|---|---|
| Purity | ≥99% |
| Formula | C32H35ClFN7O2 |
| Formula Wt. | 604.13 |
| IUPAC Name | 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile |
| Synonym | MRTX-849 |
| Appearance | White powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Zhang Y, Li C, Xia C, et al. Adagrasib, a KRAS G12c inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Commun Signal. 2022 Sep 14;20(1):142. PMID: 36104708
Sabari J, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12c-mutant non-small cell lung cancer. Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. PMID: 35404402
Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12c inhibitors, sotorasib and adagrasib, and overcoming strategies: insights form in vitro experiments. J Thorac Oncol. 2021 Aug;16(8):1321-1332. PMID: 33971321